Marcaine Spinal (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing sodium influx that is essential for depolarisation. By inhibiting nerve impulse initiation and propagation, it produces a reversible loss of sensation and motor activity in the area supplied by the affected nerves.

The specific intrathecal dose of Marcaine Spinal is determined by the prescribing clinician based on the type of procedure, patient characteristics, and desired depth of block. Exact dosing information is not provided here and should be obtained from the treating physician or official prescribing information.

Safety data for intrathecal bupivacaine during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Clinicians must assess each case individually and follow local regulatory guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine provides a longer duration of sensory and motor block, which can be advantageous for prolonged surgeries or postoperative analgesia. Ropivacaine offers a similar duration with slightly less cardiotoxicity, while bupivacaine remains a widely used choice for its potency and established safety profile when administered correctly.

Marcaine Spinal should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from direct light, moisture, and extreme temperature fluctuations. Do not freeze the solution, and inspect the vial for particulate matter before use.

The product is administered by a qualified healthcare professional via a sterile intrathecal injection into the lumbar subarachnoid space. The procedure is performed under aseptic conditions, and the patient is monitored continuously for hemodynamic and respiratory changes throughout the block.

Serious adverse events include high spinal block leading to respiratory compromise, seizures from excessive central nervous system exposure, cardiac arrhythmias or cardiac arrest due to cardiotoxicity, and rare allergic reactions. Prompt recognition and supportive management are essential if any of these complications arise.

Contraindications include patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or infection at the injection site. Caution is also advised in patients with significant hepatic impairment or pre‑existing neurologic deficits.